Neurotech International Secures FDA Rare Pediatric Disease Designation for Rett Syndrome Drug
MT Newswires Live
Oct 08, 2025
Neurotech International (ASX:NTI) has received a rare pediatric disease designation from the US Food and Drug Administration (FDA) for its lead drug candidate, NTI164, for the treatment of Rett syndrome, according to a Wednesday filing with the Australian bourse.
This milestone adds to NTI164's previously granted orphan drug designation, strengthening the company's position in developing therapies for rare neurological disorders, the filing said.
The FDA's decision was based on Rett syndrome being a serious, life-threatening, and rare condition, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.